365 related articles for article (PubMed ID: 28403980)
1. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium.
Yang JD; Mohamed EA; Aziz AO; Shousha HI; Hashem MB; Nabeel MM; Abdelmaksoud AH; Elbaz TM; Afihene MY; Duduyemi BM; Ayawin JP; Gyedu A; Lohouès-Kouacou MJ; Ndam AW; Moustafa EF; Hassany SM; Moussa AM; Ugiagbe RA; Omuemu CE; Anthony R; Palmer D; Nyanga AF; Malu AO; Obekpa S; Abdo AE; Siddig AI; Mudawi HM; Okonkwo U; Kooffreh-Ada M; Awuku YA; Nartey YA; Abbew ET; Awuku NA; Otegbayo JA; Akande KO; Desalegn HM; Omonisi AE; Ajayi AO; Okeke EN; Duguru MJ; Davwar PM; Okorie MC; Mustapha S; Debes JD; Ocama P; Lesi OA; Odeghe E; Bello R; Onyekwere C; Ekere F; Igetei R; Mah'moud MA; Addissie B; Ali HM; Gores GJ; Topazian MD; Roberts LR;
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):103-111. PubMed ID: 28403980
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study.
Ndow G; Vo-Quang E; Shimakawa Y; Ceesay A; Tamba S; Njai HF; Bojang L; Hateley C; Takao Y; Opoku E; Warsop Z; Ingiliz P; D'Alessandro U; Chemin I; Mendy M; Thursz M; Njie R; Lemoine M
Lancet Glob Health; 2023 Sep; 11(9):e1383-e1392. PubMed ID: 37517420
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
Tan DJH; Ng CH; Lin SY; Pan XH; Tay P; Lim WH; Teng M; Syn N; Lim G; Yong JN; Quek J; Xiao J; Dan YY; Siddiqui MS; Sanyal AJ; Muthiah MD; Loomba R; Huang DQ
Lancet Oncol; 2022 Apr; 23(4):521-530. PubMed ID: 35255263
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
5. Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation.
Li X; Huang L; Leng X
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2465-2474. PubMed ID: 30259149
[TBL] [Abstract][Full Text] [Related]
6. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
8. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
[TBL] [Abstract][Full Text] [Related]
9. Profile of hepatocellular carcinoma in the Republic of Moldova: first-hand information on the presentation, distribution and etiologies.
Turcanu A; Pitel E; Dumbrava VT; Tcaciuc E; Donscaia A; Peltec A; Pineau P
Rom J Intern Med; 2019 Mar; 57(1):37-46. PubMed ID: 30375353
[TBL] [Abstract][Full Text] [Related]
10. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
Hong TP; Gow PJ; Fink M; Dev A; Roberts SK; Nicoll A; Lubel JS; Kronborg I; Arachchi N; Ryan M; Kemp WW; Knight V; Sundararajan V; Desmond P; Thompson AJ; Bell SJ
Med J Aust; 2018 Oct; 209(8):348-354. PubMed ID: 30309301
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of hepatitis B and C in Egypt and Africa.
Attia MA
Antivir Ther; 1998; 3(Suppl 3):1-9. PubMed ID: 10726051
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview.
Rashed WM; Kandeil MAM; Mahmoud MO; Ezzat S
J Egypt Natl Canc Inst; 2020 Jan; 32(1):5. PubMed ID: 32372179
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma in sub-Saharan (tropical) Africa.
Balint GA; Ghebrekidan H; Balint E
Acta Med Hung; 1991; 48(3-4):177-87. PubMed ID: 1668371
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence.
Moore SW; Millar AJ; Hadley GP; Ionescu G; Kruger M; Poole J; Stones D; Wainwright L; Chitnis M; Wessels G
Cancer; 2004 Aug; 101(3):642-9. PubMed ID: 15274079
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
17. Development of hepatocellular carcinoma after successful management of esophageal variceal bleeding.
Chen WC; Lo GH; Lai KH; Cheng JS; Hsu PI; Lin CK
J Chin Med Assoc; 2004 Nov; 67(11):557-64. PubMed ID: 15720069
[TBL] [Abstract][Full Text] [Related]
18. Survival from hepatocellular carcinoma at a cancer hospital in Pakistan.
Yusuf MA; Badar F; Meerza F; Khokhar RA; Ali FA; Sarwar S; Faruqui ZS
Asian Pac J Cancer Prev; 2007; 8(2):272-4. PubMed ID: 17696722
[TBL] [Abstract][Full Text] [Related]
19. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study.
Mgaieth S; Kemp W; Gow P; Fink M; Lubel J; Nicoll A; Gazzola A; Hong T; Ryan M; Knight V; Dev AT; Sood S; Bell S; Paul E; Roberts SK
J Viral Hepat; 2017 Nov; 24(11):982-989. PubMed ID: 28414893
[TBL] [Abstract][Full Text] [Related]
20. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance.
Sellers CM; Uhlig J; Ludwig JM; Taddei T; Stein SM; Lim JK; Kim HS
Cancer Med; 2019 Oct; 8(13):5948-5958. PubMed ID: 31436905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
